Rheumatoid Arthritis: Review of development candidates.
By Christina Vasiliou, Senior Analyst
8 July 2014
I joined Datamonitor Healthcare in early 2014, having completed an MPhil in Bioscience Enterprise at the University of C...
Read full bio
The current pipeline for rheumatoid arthritis includes many new and exciting developments including novel mechanisms of action, oral formulations, and new Phase III data presented at EULAR 2014. Key opinion leaders appear optimistic about kinase and interleukin inhibitors, however, it remains to be seen how these innovative therapies will fit into an already crowded RA market.
Datamonitor Healthcare has reviewed candidates in development for rheumatoid arthritis across the US, Japan and five major EU markets (France, Germany, Italy, Spain and the UK), highlighting key trends, as well as providing analyses of clinical trial design, innovative early-stage projects and insights into how future treatment may evolve.
How will our Rheumatoid Arthritis pipeline report benefit you?
- Identify investment opportunities
Explore how the use of biomarkers will ultimately lead to a personalized medicine approach in rheumatoid arthritis allowing better matching of patients to therapies enabling you to identify commercial opportunities
- Gain competitive insight
Compare late-phase drugs against the gold-standard therapy in RA, Enbrel (etanercept; Pfizer/Amgen/Takeda) in Datamonitor Healthcare’s clinical and commercial assessment model allowing you to compare your product against the historically considered first-line anti-TNF biologic.
- Predict market share
Gain insight into how interleukin and kinase inhibitors, such as sarilumab (SAR153191, REGN88; Sanofi/Regeneron) and baricitinib (LY3009104, INCB-28050; Incyte/Eli Lilly), are expected to fit into the existing treatment paradigm for rheumatoid arthritis, enabling you to understand factors that will determine success in this market.
Key questions answered
- Which innovative early-stage drug approaches are key opinion leaders eagerly anticipating?
- How are late-stage clinical trials in RA designed? What are the key primary and secondary endpoints used to evaluate new therapies?
- How do late-phase pipeline candidates compare to marketed drugs in Datamonitor Healthcare’s drug assessment model?
- What are the unmet needs in rheumatoid arthritis and which pipeline therapies have the potential to meet these?
|Drug List:||Companies Mentioned:|
Posted in Immunology and Inflammation.